The gene expression level of transforming growth factor-β (TGF-β) as a biological prognostic marker of hepatocellular carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 3, 2005, Pages 415-421

  Ikeguchi, Masahide ^a   Iwamoto, A ^a   Taniguchi, K ^a   Katano, K ^a   Hirooka, Y ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Hepatocellular carcinoma; Real time reverse transcriptase polymerase chain reaction; Survivin; Transforming growth factor

Indexed keywords

BIOLOGICAL MARKER; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL; TUMOR GROWTH; TUMOR PROMOTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSFORMING GROWTH FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 26244433508     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mise K., Tashiro S., Yogita S., et al.: Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin. Cancer Res. 4: 1475-1482, 1998.
2. The Liver Cancer Study Group of Japan: Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74: 2772-2780, 1994.
3. Stuart K.E., Anand A.J., Jenkuns R.L.: Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 77: 2217-2222, 1996.
4. Laurent-Puig P., Legoix P., Bluteau O., et al.: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120: 1763-1773, 2001.
5. Feitelson M.A., Sun B., Tufan N.L.S., Liu J., Pan J., Lian Z.: Genetic mechanisms of hepatocarcinogenesis. Oncogene 21: 2593-2604, 2002.
6. Vivien D., Attisano L., Wrana J.L., Massague J.: Signaling activity of homologous and heterologous transforming growth factor-β receptor kinase complexes. J. Biol. Chem. 270: 7134-7141, 1995.
7. Heldin C.H., Miyazono K., ten Dijke P.: TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997.
8. Matsuura I., Denissova N.G., Wang G., He D., Long J., Liu F.: Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430: 226-231, 2004.
9. Derynck R., Akhurst R.J., Balmain A.: TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29: 117-129, 2001.
10. Freeman W.M., Walker S.J., Vrana K.E.: Quantitative PCR: pitfalls and potential. Biotechniques 26: 112-122, 1999.
11. Wittwer C.T., Hermann M.G., Moss A.A., Rasmussen R.P.: Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22: 130-138, 1997.
12. Ikeguchi M., Hirooka Y., Kaibara N.: Quantitative analysis of apotosis-related gene expression in hepatocellular carcinoma. Cancer 95: 1938-1945, 2002.
13. Liver Cancer Study Group of Japan: Classification of primary liver cancer (First English Edition). Tokyo: Kanehara, 1997.
14. Yajima T., Yagihashi A., Kameshima H., et al.: Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin. Chem. 44: 2441-2445, 1998.
15. Mitas M., Mikhitarian K., Walters C., et al.: Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int. J. Cancer 93: 162-171, 2001.
16. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., Visakorpi T.: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61: 3550-3555, 2001.
17. Nemoto T., Kitagawa M., Hasegawa M., et al.: Expression of IAP family proteins in esophageal cancer. Exp. Mol. Pathol. 76: 253-259, 2004.
18. Cheung I.Y., Cheung N.V.: Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin. Cancer Res. 7: 1698-1705, 2001.
19. Chabicovsky M., Wastl U., Taper H., Grasl-Kraupp B., Schulte-Hermann R., Bursch W.: Induction of apoptosis in mouse liver adenoma and carcinoma in vivo by transforming growth factor-β1. J. Cancer Res. Clin. Oncol. 129: 536-542, 2003.
20. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., Wang X.F.: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 92: 5545-5549, 1995.
21. Cavin L.G., Romieu-Mourez R., Panta G.R., et al.: Inhibition of CK2 activity by TGF-β1 promotes IkB-́ protein stabilization and apoptosis of immortalized hepatocytes. Hepatology 38: 1540-1551, 2003.
22. Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D.: Survivin-ΔEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59: 6097-6102, 1999.
23. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C.: Developmentally regulated expression of the novel cancer anti-apoptosis of gene survivin in human and mouse differentiation. Am. J. Pathol. 152: 43-49, 1998.
24. Azuhata T., Scott D., Takamizawa S., et al.: The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J. Pediatr. Surg. 36: 1785-1791, 2001.
25. Kato J., Kuwabara Y., Mitani M., et al.: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95: 92-95, 2001.
26. Assoian R.K., Komoriya A., Meyers C.A., Miller D.M., Sporn M.B.: Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258: 7155-7160, 1983.
27. Shariat S.F., Kim J.H., Andrews B., et al.: Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92: 2985-2992, 2001.
28. Giannelli G., Fransvea E., Marinosci F., et al.: Transforming growth factor-b1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin. Am. J. Pathol. 161: 183-193, 2002.
29. Okumoto K., Hattori E., Tamura K., et al.: Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 24: 21-28, 2004.